Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Recursion Pharmaceuticals, Inc. (RXRX) had Income from Continuous Operations of $-117.50M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$6.47M |
|
$-117.50M |
|
$12.49M |
|
$-6.02M |
|
$134.98M |
|
$-128.50M |
|
$6.40M |
|
$-122.11M |
|
$-122.11M |
|
$-117.50M |
|
|
Income from Continuous Operations |
$-117.50M |
$-117.50M |
|
$-117.50M |
|
$-128.50M |
|
$-108.83M |
|
529.30M |
|
529.30M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$709.56M |
|
$95.81M |
|
$629.97M |
|
$1.34B |
|
$129.70M |
|
$7.18M |
|
$185.05M |
|
$314.75M |
|
$1.02B |
|
$570.53M |
|
$1.02B |
|
530.63M |
|
| Cash Flow Statement Financials | |
$-81.10M |
|
$-0.34M |
|
$-3.47M |
|
$753.92M |
|
$665.18M |
|
$-88.74M |
|
$22.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.47 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-92.99% |
|
-1985.55% |
|
-1985.55% |
|
-- |
|
-1886.71% |
|
-1815.58% |
|
$-81.36M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.48 |
|
188.91 |
|
-11.47% |
|
-20.60% |
|
-8.77% |
|
-11.39% |
|
$1.93 |
|
$-0.15 |
|
$-0.15 |
|